01 — The Text
What.
- Extends federal funding and oversight for stem cell research and therapeutic development programs that were set to expire.
- Updates regulatory framework governing how stem cell treatments move from lab to patient care.
- Establishes reauthorization timeline for continued NIH and related agency stem cell initiatives.
02 — The Stakes
So what?
- Biomedical researchers and hospitals gain continued federal support for regenerative medicine work on diseases like Parkinson's and spinal injury.
- Patients with degenerative conditions may access experimental therapies faster if regulatory pathways are streamlined.
- Detailed policy specifics unavailable until full text released — stakes unclear on funding levels, eligibility rules, or regulatory changes.
03 — The Path
Now what?
- Bill cleared committee 48-0 in May 2026 and moved to House floor in July — full chamber vote likely within weeks.
- Contact your House representative to learn their position on stem cell research reauthorization before floor vote.
Legislative History
Actions.
- Jul 2, 2026 — Placed on the Union Calendar, Calendar No. 629.
- Jul 2, 2026 — Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-724.
- Jul 2, 2026 — Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-724.
- May 21, 2026 — Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0.
- May 21, 2026 — Committee Consideration and Mark-up Session Held
- May 13, 2026 — Forwarded by Subcommittee to Full Committee by Voice Vote.
- May 13, 2026 — Subcommittee Consideration and Mark-up Session Held
- Sep 4, 2025 — Referred to the Subcommittee on Health.